Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

China Tourism Group Duty Free / Equity Capital Markets

<ul>
<li>Aequitas Research puts out a weekly update on the deals that were covered by the team recently along with updates for upcoming IPOs.</li>
<li>On the IPO front, China Tourism's listing appears to have set the ball rolling for others to follow.</li>
<li>After a flurry of activity in the prior week, there weren't any major placements this week.</li>
</ul>


Aequitas Research puts out a weekly update on the deals that were covered by the team recently along with updates for upcoming IPOs.
On the IPO front, China Tourism's listing appears to have set the ball rolling for others to follow.
After a flurry of activity in the prior week, there weren't any major placements this week.


ECM Weekly (28th Aug 2022) - China Tourism, BA REIT, Hongjiu Fruit, YH Ent, Biocyto, WM, APM, Daiwa

Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Biocytogen Pharmaceuticals / Equity Capital Markets

<ul>
<li>Biocytogen is a leading animal model player in China expanding into biotech. The company launched a downsized deal to  raise up to USD 70m via a Hong Kong listing.</li>
<li>In our previous note, we looked at the company business lines and compared the company's operation with leading animal model players.</li>
<li>In this note, we provide an update for the book building. We provide our quick thoughts on the valuation and deal dynamics.</li>
</ul>


Biocytogen is a leading animal model player in China expanding into biotech. The company launched a downsized deal to  raise up to USD 70m via a Hong Kong listing.
In our previous note, we looked at the company business lines and compared the company's operation with leading animal model players.
In this note, we provide an update for the book building. We provide our quick thoughts on the valuation and deal dynamics.


Biocytogen (百奥赛图) IPO: Short Term and Long Term Challenges

Equity Analyst, LightStream Research

Shifara Samsudeen, FCMA, CGMA

Equity Analyst

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

<ul>
<li>
<a href="https://www.smartkarma.com/entities/biocytogen-pharmaceuticals-beijing-co-ltd" target="_blank" data-smartkarma-citation="entities:34533:1" rel="noopener">Biocytogen Pharmaceuticals (Beijing) (BCP HK)</a> is a biopharmaceutical and pre-clinical research services company with two core products (YH003 and YH001) and 10 other pipeline candidates.</li>
<li>The company currently does not have any commercialised products and earns revenue through offering pre-clinical research services and antibody development.</li>
<li>Biocytogen’s business model comes with inherent risks such as absence of approved drugs. Hence, we would recommend staying on the side line.</li>
</ul>



Biocytogen Pharmaceuticals (Beijing) (BCP HK) is a biopharmaceutical and pre-clinical research services company with two core products (YH003 and YH001) and 10 other pipeline candidates.
The company currently does not have any commercialised products and earns revenue through offering pre-clinical research services and antibody development.
Biocytogen’s business model comes with inherent risks such as absence of approved drugs. Hence, we would recommend staying on the side line.


Biocytogen Pharma IPO: Large Drug Pipeline but Negatives Outweighs the Positives

APAC IPOs & Placements, Aequitas Research

Clarence Chu

APAC IPOs & Placements

<ul>
<li>Aequitas Research puts out a weekly update on the deals that were covered by the team recently along with updates for upcoming IPOs.</li>
<li>Placements continued to take center stage this week, beginning with Uber’s clean-up sale of Zomato.</li>
<li>Socar launched its one-day bookbuild earlier in the week. We continued looking at the upcoming deals in our pipeline. </li>
</ul>


Aequitas Research puts out a weekly update on the deals that were covered by the team recently along with updates for upcoming IPOs.
Placements continued to take center stage this week, beginning with Uber’s clean-up sale of Zomato.
Socar launched its one-day bookbuild earlier in the week. We continued looking at the upcoming deals in our pipeline. 


ECM Weekly (7th Aug 2022) - Zomato, Orica, China Tourism, Hongjiu Fruit, Giant Biogene, Socar

<ul>
<li>Biocytogen, a China-based pre-clinical research and biopharmaceutical company, will pre-market its IPO to raise USD 25m, which is a significant downsize from the previous USD 300m fundraising target.</li>
<li>In our previous note, we covered the company's fundamentals and compared its business with its peers.</li>
<li>We will provide an update on its latest prospectus and its peer performance in this note.</li>
</ul>


Biocytogen, a China-based pre-clinical research and biopharmaceutical company, will pre-market its IPO to raise USD 25m, which is a significant downsize from the previous USD 300m fundraising target.
In our previous note, we covered the company's fundamentals and compared its business with its peers.
We will provide an update on its latest prospectus and its peer performance in this note.


Biocytogen (百奥赛图) Pre-IPO: Prospectus and Valuation Updates

China

Biocytogen Pharmaceuticals is a global biotechnology company focused on the research and development of novel antibody-based drugs and preclinical research services. It offers gene-editing services, preclinical pharmacology and efficacy evaluation, and sells animal models under its BioMice™ sub-brand. The company also utilizes its proprietary RenMice® platforms for fully human antibody discovery. It was founded in 2008 and is headquartered in Beijing, China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Biocytogen Pharmaceuticals (2315 HK)

ECM Weekly (28th Aug 2022) - China Tourism, BA REIT, Hongjiu Fruit, YH Ent, Biocyto, WM, APM, Daiwa

Aequitas Research puts out a weekly update on the deals that were covered by the team recently along with updates for upcoming IPOs.

Sumeet Singh

Biocytogen (百奥赛图) IPO: Short Term and Long Term Challenges

Biocytogen launched a downsized deal. We look at the deal terms, dynamics and provided an updated thought on the deal. We think the company's...

Ke Yan, CFA, FRM

Biocytogen Pharma IPO: Large Drug Pipeline but Negatives Outweighs the Positives

Biocytogen doesn't have any products approved and are in early stages of development. Some competing drugs are in advanced phases. Pre-clinical...

Shifara Samsudeen, FCMA, CGMA

ECM Weekly (7th Aug 2022) - Zomato, Orica, China Tourism, Hongjiu Fruit, Giant Biogene, Socar

Aequitas Research puts out a weekly update on the deals that were covered by the team recently along with updates for upcoming IPOs.

Clarence Chu

Biocytogen (百奥赛图) Pre-IPO: Prospectus and Valuation Updates

Biocytogen plans to pre-market its much downsized Hong Kong IPO next week. We provide an update from its prospectus and the peer performance.

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)